X-Zell US

X-ZELL is a fully integrated biotechnology company specialising in rare cell detection technology.

Established in 2009 with investment from Vichit Suraphongchai – one of the leading figures in Southeast Asian banking – and support from Thailand’s premier science university, Mahidol University, X-ZELL first made headlines when it was accepted into Y Combinator’s ‘W15 Winter Batch’.

The company used the opportunity to demonstrate the utility of its technologies to reliably detect prostate cancer at an early stage, before it spreads, securing a rare Honourable Mention and funding by US start-up guru, Paul Buchheit – the creator and lead developer of Gmail – as well as six other Silicon Valley-based angel investors.

Following a successful seed round, X-ZELL opened a Silicon Valley Office in Sunnyvale, California, in 2016, which is supported by X-ZELL’s Global R&D Hub in Bangkok, Thailand.